Science & ResearchAug 25, 2026
Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study.
There are currently no licensed vaccines for disease caused by Bundibugyo virus (BDBV).
There are currently no licensed vaccines for disease caused by Bundibugyo virus (BDBV). The recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been widely deployed during Ebola virus disease outbreaks caused by Ebola virus (EBOV).…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.